Background: Pembrolizumab had been proven effective in MSI-H metastatic colon cancer after chemotherapy. This was thought to be due to the specific characteristic of the tumor to unable to repair DNA-damage because of deficient mismatched repair proteins. This is postulated to lead to increased tumor antigen expression and enhanced sensitivity to immuno…
Keep reading with a 7-day free trial
Subscribe to Hematology Oncology Snippets to keep reading this post and get 7 days of free access to the full post archives.